148 related articles for article (PubMed ID: 7789083)
1. [Treatment of chronic obliterative arteriopathy of the legs in the second Fontaine's stage. Personal experience with a buflomedil-pentoxifylline-defibrotide combination].
Marci M; Albiani B; Ricci M; Russo F
Clin Ter; 1995 Mar; 146(3):211-4. PubMed ID: 7789083
[TBL] [Abstract][Full Text] [Related]
2. [Clinical experience and instrumental evaluation of buflomedil hydrochloride in the therapy of chronic obliterative arteriopathies of the legs].
Lucisano V; Margheriti R; Matone P; Morrieri C; Rugolo A; Corsi V
Clin Ter; 1986 Jun; 117(6):499-509. PubMed ID: 3527536
[No Abstract] [Full Text] [Related]
3. [Vascular and hemorheologic effects of buflomedil chlorhydrate in chronic obliterative arteriopathies of the legs].
Coglitore S; Manganaro A; Barbera MC; Cento D; Buda D; Arrigo F; Consolo F
Minerva Cardioangiol; 1986 Nov; 34(11):745-9. PubMed ID: 2949163
[No Abstract] [Full Text] [Related]
4. [Clinical experience in patients with chronic peripheral obliterating arteriopathy: defibrotide versus definite molecular weight heparan sulfate (MW 7500-15000 dalton)].
Michelini S; Micci A; Failla A; Grechi G; Iantaffi A
Minerva Cardioangiol; 1996; 44(1-2):33-7. PubMed ID: 8767620
[TBL] [Abstract][Full Text] [Related]
5. [Doppler flowmeter evaluation of the effects of the administration of buflomedil (irrodan) on peripheral circulation in patients with obstructive chronic arteriopathy].
Abate S; Ferulano GP; Vanni L; Dilillo S; Picilli M; D'Alessio E
Minerva Cardioangiol; 1985 Nov; 33(11):749-56. PubMed ID: 2935748
[No Abstract] [Full Text] [Related]
6. Effects of defibrotide on physical performance and hemorheologic picture in patients with peripheral arteriopathy.
Marrapodi E; Leanza D; Giordano S; Nazzari M; Corsi C
Clin Trials Metaanal; 1994 Apr; 29(1):21-30. PubMed ID: 10150182
[TBL] [Abstract][Full Text] [Related]
7. Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II. A review.
Spitzer S; Bach R; Schieffer H
Int Angiol; 1992; 11(3):204-10. PubMed ID: 1460355
[TBL] [Abstract][Full Text] [Related]
8. Defibrotide and peripheral obliterative arterial disease: preliminary data.
Arosio E; Pancera P; Zannoni M; Arcaro G; Priante F; Lechi A
Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):526-9. PubMed ID: 2533180
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the effectiveness of buflomedil and pentoxifylline in patients with arterial occlusive disease.
Trübestein G; Trübestein R; Duong QD
Angiology; 1981 Oct; 32(10):705-10. PubMed ID: 7034591
[TBL] [Abstract][Full Text] [Related]
10. Effects of oral and intravenous defibrotide on blood viscosity in patients with peripheral obliterative arterial disease.
Belfiglio A; Traietti P; Bologna E; Salvo G
Clin Ther; 1989; 11(4):479-84. PubMed ID: 2776165
[TBL] [Abstract][Full Text] [Related]
11. Effects of PGE-1 in patients suffering from peripheral arterial occlusive disease.
Milio G; Cospite V; Cospite M
Minerva Cardioangiol; 2003 Jun; 51(3):311-6. PubMed ID: 12867883
[TBL] [Abstract][Full Text] [Related]
12. [Effect of buflomedil perfusion on peripheral tissue oxygenation during transluminal angioplasty in patients with advanced arteriopathy of the lower limbs].
Joffre F; Meites G; Rousseau H; Staffin C; Allaert FA; Pelat P
Ann Radiol (Paris); 1994; 37(3):239-44. PubMed ID: 8092756
[TBL] [Abstract][Full Text] [Related]
13. [Action and tolerability of delayed-action buflomedil in obliterating arteriopathies of the lower limbs. A multicenter study].
Andreozzi GM; Lepore R
Clin Ter; 1990 Nov; 135(4):273-81. PubMed ID: 2150026
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease.
Strano A; Fareed J; Sabbá C; Albano O; Allegra C; Carlizza A; Binaghi F; Fronteddu F; Del Guercio R; Arpaia MR
Semin Thromb Hemost; 1991; 17 Suppl 2():228-34. PubMed ID: 1948094
[TBL] [Abstract][Full Text] [Related]
15. Buflomedil in arterial occlusive disease: results of a controlled multicenter study.
Trübestein G; Balzer K; Bisler H; Klüken N; Muller-Wiefel H; Unkel B; Mahfoud Y; Ziegler W
Angiology; 1984 Aug; 35(8):500-5. PubMed ID: 6383127
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological preconditioning of ischaemia.
Laghi Pasini F; Capecchi PL; Acciavatti A; Petri S; de Lalla A; Cati G; Colafati M; Di Perri T
Clin Hemorheol Microcirc; 1997; 17(1):73-84. PubMed ID: 9181761
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs.
Chacón-Quevedo A; Eguaras MG; Calleja F; Garcia MA; Roman M; Casares J; Muñoz I; Concha M
Angiology; 1994 Jul; 45(7):647-53. PubMed ID: 8024164
[TBL] [Abstract][Full Text] [Related]
18. A pilot evaluation of the effect of defibrotide in patients affected by peripheral arterial occlusive disease.
Sabbá C; Zupo V; Dina F; Nazzari M; Albano O
Int J Clin Pharmacol Ther Toxicol; 1988 May; 26(5):249-52. PubMed ID: 3045026
[TBL] [Abstract][Full Text] [Related]
19. [Buflomedil in arterial occlusive disease. Results of a controlled study].
Trübestein G; Balzer K; Bisler H; Klüken N; Mahfoud Y; Müller-Wiefel H; Unkel B; Ziegler W
Dtsch Med Wochenschr; 1982 Dec; 107(51-52):1957-61. PubMed ID: 6756854
[No Abstract] [Full Text] [Related]
20. [Buflomedil chlorhydrate in peripheral vasculopathies].
Dall'Antonia F; Perbellini A; Adami CA; Dal Cortivo G; Bucci S
Clin Ter; 1986 Dec; 119(5):379-85. PubMed ID: 2951055
[No Abstract] [Full Text] [Related]
[Next] [New Search]
